Mayo Clinic Pharmacy Grand Rounds

Oral Antibiotics in Infective Endocarditis (IE): No Longer a Tough Pill to Swallow?

Kyle Wamsley, Pharm.D. (@KyleWamsley1) discusses current literature surrounding the use of oral antimicrobials in the treatment of infective endocarditis (IE), identifies specific patient populations in whom it may be appropriate to consider oral therapy for the treatment of IE, and outlines oral antimicrobial regimens which may be most appropriate for use in the treatment of IE.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

It’s Not Just the Lungs? Non-Pulmonary Complications of Cystic Fibrosis

Ashley Otto, Pharm.D., BCPS describes the pathophysiology of non-pulmonary clinical manifestations in cystic fibrosis (CF), reviews guideline recommendations and primary literature to manage non-pulmonary CF complications, and selects appropriate treatment options for patients with non-pulmonary CF complications. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Are you a 10/10? Tenecteplase in Ischemic Stroke

Cassandra Schmitt, Pharm.D. (@cjschmitt2) describes the differences between thrombolytic agents used for the treatment of ischemic stroke, discusses the literature examining the efficacy and safety outcomes of tenecteplase, and identifies the role of tenecteplase in ischemic stroke thrombolysis.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

PIC-ing Up on Post-Intensive Care Syndrome: Current Care Gaps and Strategies for Management

Shannon Piche, Pharm.D., BCPS describes the incidence and clinical manifestation of PICS, reviews literature examining the long term implications of critical illness, and discusses current strategies to address care gaps related to PICS symptom recognition and management.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

 

Breaking the Bank: Financial Toxicity in Oncology

Allison Golbach, Pharm.D., BCPS (@AllisonGPharmD) reviews the definition, background, and measurement of financial toxicity, discusses the impact of financial toxicity on patients’ clinical outcomes, and identifies methods to help patients make informed decisions about their oncology care.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Hitting the rESETT Button: Updates in Status Epilepticus Treatment

Kellyn Engstrom, Pharm.D., MPH (@KellynEPharmD) reports on current guideline recommendations and gaps in evidence for the treatment of status epilepticus, interprets recent evidence regarding conventional antiepileptic utilization in status epilepticus, and lists three considerations in applying new evidence for status epilepticus treatment into clinical practice.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

CaLLing Targeted Therapies: Advancements in Chronic Lymphocytic Leukemia

Mikhaila Rice, Pharm.D., BCPS (@MikhailaPharmD) reviews chronic lymphocytic leukemia diagnosis and historical treatment options, describes the pharmacology of Bruton tyrosine kinase inhibitors and venetoclax, and discusses the use of targeted agents as first line therapy for chronic lymphocytic leukemia.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

No Gout About It: Updates in the Management of Gout

Madison Fazio, Pharm.D. (@madison_fazio) discusses new guideline recommendations for the management of gout, reviews the literature contributing to the new gout recommendations, and recognizes patients that would benefit from newer gout therapies based on guideline recommendations. 

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Alpha-1 and 1 for All: Evaluating the Role of Midodrine for Vasopressor Discontinuation

Natalie Haddad, Pharm.D. (@NatalieHaddadRx) explains the mechanism of action of midodrine, reviews the current evidence for midodrine and its impact on vasopressor discontinuation and identifies midodrine’s role in therapy for vasopressor discontinuation.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Bypassing Subtherapeutic Anticoagulation: DOACs vs. Warfarin After Bariatric Surgery

Danielle Hess, Pharm.D. (@dhess_09) describes the potential effects of bariatric surgery on drug pharmacotherapy measures due to altered gastrointestinal anatomy, reviews literature pertaining to warfarin use after bariatric surgery and discusses safety and efficacy of direct-acting oral anticoagulants (DOACs) following bariatric surgery.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.